""There are signals that GLP-1s could be the first true longevity drug," Alex Zhavoronkov, the founder and CEO of Insilico Medicine, said Monday at the Fortune Innovation Forum in Kuala Lumpur, Malaysia."
""They found that the regular intake of this drug may reduce the incidence of many age-related diseases, including some CNS (central nervous system) disorders, liver disease, and kidney disease," Zhavoronkov said."
""There's an "obesity pandemic," said Adele Wong, a dietitian and nutritionist from Nutrition Track, on Monday."
""It's still in its early stages," Wong noted."
GLP-1 receptor agonists, long used for type-2 diabetes, surged in public attention after weight-loss approvals such as Wegovy and Zepbound. Early signals from experts and companies suggest regular GLP-1 use may lower the incidence of multiple age-related conditions, including certain central nervous system disorders, liver disease, and kidney disease, indicating possible longevity effects. Global obesity rates are rising as emerging markets urbanize and adopt more sedentary lifestyles, with projections that over half of adults could be overweight or obese by 2050. Malaysia already faces high obesity prevalence, substantial economic costs, and slow GLP-1 uptake due to stigma.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]